Better Targets for Better Drugs
Using AI to unveil the Drivers of Disease for Better Drug Discovery
At Intelligent OMICS Ltd. (Intellomx), we are revolutionizing the field of drug discovery by leveraging the power of Artificial Intelligence (AI) and Machine Learning (ML). Our cutting-edge technology delves deep into transcriptomic, genomic and proteomic data sets to uncover novel biological targets and validate existing pathways, paving the way for groundbreaking treatments.
​
Our Mission
Our mission is to transform the landscape of pharmaceutical research by identifying the key drivers of disease. Through our innovative approach, we aim to accelerate the discovery of new drugs, making the process faster, more efficient, and cost-effective.
​
Join Us in Shaping the Future of Medicine
Discover how Intellomx can help you unlock the potential of your research and drive better drug discovery. Contact us today to learn more about our services and how we can collaborate to make a difference.
​
Together, let’s unveil the drivers of disease and create a healthier future.
Our Services
Intellomx offers a range of services to our clients and collaboration partners.
Please contact us for a confidential discussion.
Pathway
Discovery
Intellomx technology identifies the key drivers in disease pathways, revealing the underlying systems biology of multiple diseases.
Digital
Twin
Our Digital Twin provides a platform for rapid testing of off-target effects via disease pathways, saving costs and unnecessary animal trials. This is a major break-through
Novel Drug Discovery
Intellomx technology uses proprietary artificial neural network algorithms to model non-linear biology, finding patterns that could not previously have been identified.
Intuitive Intelligence
Our non-linear discovery tools are highly suited to the analysis of complex biological data from multiple sources resulting in novel outcomes in a fraction of the time taken by traditional research.
Novel Outcomes for New Drugs
Our proprietary approach to AI eliminates potential drugs that would fail in development, saving up to 90% of pre-clinical drug development costs in a portfolio, in response to industry demands.
Companion Diagnostics
Intellomx technology optimises diagnostic panels and creates companion diagnostics with the minimum number of biomarkers - ideal for lateral flow devices, PCR or similar platforms.
Testimonials
"I love this collaboration already – in under 4 weeks you have provided a clearer picture of [disease] than we have achieved from 4 years of hard work. Let’s move to the next level!"
Philippe Moingeon
Director, Servier Pharmaceuticals